Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285351 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL2805477 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL514303 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL5651324 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL581064 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL2305639 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL5356778 | 0.98 | CES1 (0.35) | CES1 | |
| SCHEMBL290664 | 0.94 | — | — | |
| SCHEMBL57967 | 0.85 | — | — | |
| SCHEMBL2828995 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025083472-A2 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085815-A1 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119421709-A | Indazole-containing macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-110128315-B | Compound, preparation method and application thereof, and glycosidase inhibitor | 中国科学院化学研究所 | 2021-08-20 | — | — | CN | disclosed |
| US-20050186580-A1 | Quality control method for array manufacture | AGILENT TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050186579-A1 | MALDI-MS analysis of nucleic acids bound to a surface | AGILENT TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050048496-A1 | Method of polynucleotide synthesis using modified support | AGILENT TECHNOLOGIES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050048601-A1 | Method for polynucleotide synthesis | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-03 | — | — | US | disclosed |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2005-03-03 | — | — | US | disclosed |
| EP-1510522-A1 | Method of polynucleotide synthesis using modified support | Agilent Technologies Inc (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6710048-B2 | SELECTIVE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; TO TREAT SOLID-TUMOR CANCERS, ANGIOGENESIS, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, ENDOMETRIOSIS AND PSORIASIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1330452-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002024681-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048496-A1 | Method of polynucleotide synthesis using modified support | POLN, POLRMT, POLM | CES1 4268/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | CES1 1157/4885 |
| US-20050048601-A1 | Method for polynucleotide synthesis | POLN, RNGTT, NSUN2 | CES1 3226/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | CES1 1956/4885 |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | TYMP, POLN, CPSF1 | CES1 2420/4885 |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | FLT1, FLT4, KDR | CES1 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.